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Neurobiology of Disease

Acute ␥-Secretase Inhibition of Nonhuman Primate CNS
Shifts Amyloid Precursor Protein (APP) Metabolism from
Amyloid-␤ Production to Alternative APP Fragments
without Amyloid-␤ Rebound
Jacquelynn J. Cook,3* Kristin R. Wildsmith,1* David B. Gilberto,4 Marie A. Holahan,3 Gene G. Kinney,5
Parker D. Mathers,4 Maria S. Michener,3 Eric A. Price,5 Mark S. Shearman,5 Adam J. Simon,5 Jennifer X. Wang,2
Guoxin Wu,5 Kevin E. Yarasheski,2 and Randall J. Bateman1
Departments of 1Neurology and 2Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, and Departments of 3Imaging,
4Laboratory Animal Resources, and 5Neuroscience, Merck Research Laboratories, West Point, Pennsylvania 19486

The accumulation of amyloid ␤ (A␤) in Alzheimer’s disease is caused by an imbalance of production and clearance, which leads to
increased soluble A␤ species and extracellular plaque formation in the brain. Multiple A␤-lowering therapies are currently in development: an important goal is to characterize the molecular mechanisms of action and effects on physiological processing of A␤, as well as
other amyloid precursor protein (APP) metabolites, in models which approximate human A␤ physiology. To this end, we report the
translation of the human in vivo stable-isotope-labeling kinetics (SILK) method to a rhesus monkey cisterna magna ported (CMP)
nonhuman primate model, and use the model to test the mechanisms of action of a ␥-secretase inhibitor (GSI). A major concern of
inhibiting the enzymes which produce A␤ (␤- and ␥-secretase) is that precursors of A␤ may accumulate and cause a rapid increase in A␤
production when enzyme inhibition discontinues. In this study, the GSI MK-0752 was administered to conscious CMP rhesus monkeys in
conjunction with in vivo stable-isotope-labeling, and dose-dependently reduced newly generated CNS A␤. In contrast to systemic A␤
metabolism, CNS A␤ production was not increased after the GSI was cleared. These results indicate that most of the CNS APP was
metabolized to products other than A␤, including C-terminal truncated forms of A␤: 1-14, 1-15 and 1-16; this demonstrates an alternative
degradation pathway for CNS amyloid precursor protein during ␥-secretase inhibition.

Introduction
The amyloid hypothesis proposes that the accumulation of
amyloid-␤ (A␤) in the brain leads to a cascade of events culminating in Alzheimer’s disease (AD) (Hardy and Selkoe,
2002; Golde, 2005). A␤ is generated by the sequential cleavage
of amyloid precursor protein (APP) by ␤-secretase and
␥-secretase (Blennow et al., 2006; Steiner et al., 2008; Wolfe,
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2008b). A␤ accumulation in the form of insoluble plaques and
soluble monomers and oligomers develops due to an imbalance in the production and clearance of these A␤ forms in the
CNS.
Because A␤ is a major therapeutic target, multiple A␤-lowering
strategies are under development, such as increasing clearance (including A␤ immunization approaches) or decreasing production by
inhibition of ␤-secretase or ␥-secretase (Hock et al., 2003; Lemere et
al., 2004; Vassar, 2004; Wolfe, 2008a; Tomita, 2009). ␥-Secretase is a
complex of integral membrane proteins that are present in most
cells, but may have different functions depending on cell type
(Steiner et al., 2008). ␥-Secretase inhibitors (GSIs) target the
␥-secretase complex to inhibit the production of A␤ from the ␤-Cterminal fragment of APP. However, GSIs also inhibit notch processing, thereby interfering with the critical role of notch in signaling
cell differentiation in the immune system and gastrointestinal tract
(Maillard et al., 2003; Stanger et al., 2005). Chronic inhibition with a
GSI leads to mechanism-based toxic side-effects (Searfoss et al.,
2003; Wong et al., 2004), which may be avoided by using partial or
intermittent ␥-secretase inhibition. However, there is a concern that
when ␥-secretase inhibition is partial or intermittent, accumulated
APP products, including the ␤-C-terminal fragment, will result in
A␤ overshoot or rebound.

6744 • J. Neurosci., May 12, 2010 • 30(19):6743– 6750

After GSI treatment, a rebound in levels of A␤ above placebo
is consistently observed in plasma of humans and animal models
(Lanz et al., 2004, 2006; Michener et al., 2006; Rosen et al., 2006;
Siemers et al., 2006). In addition, an early elevation in plasma
A␤40 has also been observed in rhesus monkeys at GSI doses that
do not reduce plasma A␤40 (Michener et al., 2006). Although an
overshoot was reported in the CNS of a rat model (Burton et al.,
2008), it has not been observed in the CNS of human volunteers
(Rosen et al., 2006) or other animal models (Lanz et al., 2004).
The contrasting results observed in plasma versus the CNS highlight the separation of the periphery from the CNS and indicate
potentially different molecular mechanisms of A␤ production
and APP processing. As increased concentrations of A␤ in the
CNS are expected to be harmful, it is important to demonstrate
that candidate compounds are truly targeting A␤ generation in
the CNS. Clarification of the specific effect on the processing of
APP metabolites is also important for the selection of optimal
compounds for development. As few treatments or conditional
experiments can be evaluated in humans, we translated a recently
described stable-isotope-labeling kinetic (SILK) method (Bateman
et al., 2006) to a nonhuman primate model for testing of therapeutics
and molecular mechanisms. By administering stable-isotopes in
conjunction with a GSI, the effect of inhibition on A␤ production
was measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). Similar to results seen in humans (Bateman et al.,
2009), there was a dose-related decrease in A␤ production in response to ␥-secretase inhibition without an overshoot of either
newly generated or total levels of A␤.

Materials and Methods
Cisterna magna ported rhesus monkey model. All procedures related to the
use of animals in these studies were reviewed and approved by the Institutional Animal Care and Use Committee at Merck Research Laboratories at West Point, and conform with the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Resources, National
Research Council, 1996). The chronically implanted cisterna magna
catheter and port system provides for noninvasive collection of uncontaminated CSF samples and the capability for repeat sampling. This
chronic system allows for longitudinal studies and comparison to historical data within the same monkeys. A customized flexible silicone catheter (SoloCath) is freely suspended in the cisterna magna, anchored firmly
on both sides of the atlanto-occipital membrane, and tunneled subcutaneously to the midscapular region where it is fed into a surgically implanted port body. CSF is accessed by aseptically inserting a needle
through the skin and membrane covering the port into the reservoir of
the port body (Gilberto et al., 2003); CSF flows through the cannulation
system without the need for active withdrawal. These monkeys are also
implanted with a standard catheter system in the jugular vein (titanium
vascular access port by SoloPort) for chronic vascular access used for the
13
C6-leucine infusions.
13
C6-Leucine infusion protocol. In preparation for each experiment,
rhesus monkeys were restricted to a diet of vegetables and fruit for a 24 h
period before the start of the 13C6-leucine infusion; all food was removed
⬃17 h before dosing. Vegetables and fruit were provided again after the
8 h sample collection (during the infusion) and the normal diet of monkey chow (includes protein) was given after the termination of the infusion (⫹12 h in the final standard protocol). Conscious monkeys were
transferred to the laboratory and placed in primate restraint chairs; a 22 g
Huber needle (Instech) connected to a sterile adapter was inserted into
the port body to prepare the cisterna magna catheter and port system for
CSF sampling. A sterile stock solution of 13C6-leucine (Cambridge Isotope Laboratories, CLM-2262) was made fresh daily for each study at 15
or 7.5 mg/ml in saline for the high (8 mg/kg ⫹ 8 mg/kg/h) and low (4
mg/kg ⫹ 4 mg/kg/h) leucine infusions, respectively. The 13C6-leucine
was infused in the chronic vascular access port at ⬃0.5 ml/min or ⬃0.1
ml/min for the bolus and 12 or 21 h infusions (exact rate was normalized

Cook et al. • GSI Demonstrates Alternative APP Metabolic Pathway

for body weight). Baseline CSF and blood samples were collected 1 h
before the start of the 10 min primed bolus injection. In the final, optimized (12 h) protocol, plasma and CSF samples were also collected following the initiation of the 13C6-leucine infusion at 2 h (11:00 A.M.), 4 h
(1:00 P.M.), 6 h (3:00 P.M.), 8 h (5:00 P.M.), 12 h (9:00 P.M., end of
infusion), 15 h (12:00 A.M.), 18 h (3:00 A.M.), 21 h (6:00 A.M.), 24 h
(9:00 A.M., day 2), 27 h (12:00 P.M.), 30 h (3:00 P.M.), 33 h (6:00 P.M.),
36 h (9:00 P.M., day 3) and 39 h (12:00 P.M.). CSF (1 ml) was collected
per time point, and samples were separated into aliquots and transferred
to various laboratories for blinded analyses.
␥-Secretase inhibitor study protocol. The Merck ␥-secretase inhibitor,
MK-0752, was previously characterized for in vivo pharmacokinetics and
efficacy, and demonstrated decline of CSF A␤40 levels in healthy human
volunteers (Rosen et al., 2006). MK-0752 is a moderately potent
␥-secretase inhibitor, showing dose-dependent reduction of A␤40 with
an IC50 of 5 nM in human SH-SY5Y cells. Dose-dependent reductions in
plasma, brain and CSF A␤40 were observed in guinea-pigs following
single oral doses of 10 –30 mg/kg (brain IC50 ⫽ 440 nM). Concentration
required for 50% reduction of brain A␤40 was 318 and 154 nM in APPYAC and Tg2576 mice, respectively. For the purposes of the current
study, 60 and 240 mg/kg dose of MK-0752 were selected to elicit intermediate and near complete CSF A␤ reduction for evaluating the potential effects on A␤ production and clearance. A 3-way crossover
randomized design with 2 week intervals between doses in cisterna
magna ported (CMP) rhesus monkeys was used (n ⫽ 6 male rhesus
monkeys; n ⫽ 5 at 6 –9 years and n ⫽ 1 at 17 years at time of study; 7–9.5
kg). MK-0752 (60 or 240 mg/kg) or vehicle (water) was administered
orally to conscious, chaired rhesus monkeys 1 h before the initiation of
the primed 12 h 13C6-leucine constant infusion (4 mg/kg ⫹ 4 mg/kg/h).
CSF and plasma samples were collected as described above for determination of MK-0752 concentrations, A␤40 (ELISA), 13C6-leucine labeling
of A␤, and free 13C6-leucine enrichment.
To fully characterize the rebound beyond baseline in plasma A␤40, a
follow-up study was conducted. Six rhesus monkeys (n ⫽ 3/group) were
treated orally with vehicle or 240 mg/kg MK-0752. CSF and plasma samples were collected as described for the optimized protocol with the addition of time points through 240 h postdose (48, 72, 144, 168, 216,
240 h).
Amyloid ␤ ELISA. Solid black 96 well Nunc plates were coated with 3
g/ml N-terminal A␤ antibody 6E10 (Signet) in pH 9.4 bicarbonate
buffer overnight at 4°C, washed with PBS with 0.1% Tween 20, and
blocked with 3% BSA in PBS (BSA/PBS) for 3 h. CSF samples for the
A␤1-40 assay were diluted 1:8 in BSA/PBS; 50 l of samples and standards, starting at 4:00 P.M., were loaded onto the plate. CSF samples for
A␤1-42 were diluted 1:4 in BSA/PBS and 100 l of samples and standards, starting at 2:00 P.M., were loaded onto the plate. Plasma samples
were diluted 1:4 in BSA/PBS and 50 l of samples and standards, starting
at 4:00 P.M., were loaded onto the plate. Fifty microliters of G2-10alkaline phosphatase (A␤1-40) or 12F4-alkaline phosphatase (A␤1-42)
diluted in BSA/PBS was added to the plate and incubated overnight at
4°C. Plates were washed 3 times in PBS with 0.1% Tween 20 and 100 l of
alkaline phosphatase substrate Tropix CDP-star (Applied Biosystems)
was added for 30 min. Luminescence was measured using a PerkinElmer
Envision plate reader.
Amyloid ␤ immunoprecipitation. Antibody beads were prepared by
covalently binding 4G8 antibody (GE Healthcare) (recognizes A␤ residues 18-22) or 6E10 antibody (Covance) (recognizes A␤ residues 1-17)
to CNBr Sepharose beads (GE Healthcare) at a concentration of 10
mg/ml antibody (according to the manufacturer’s protocol). The antibody beads were stored at 4°C in a 50% slurry of PBS 0.02% azide.
4G8 immunoprecipitation. CSF (500 l) was diluted 1:1 with PBS.
Protease inhibitors (40 g/ml aprotinin and 20 g/ml leupeptin) (Calbiochem), 30 l of antibody-bead slurry, and guanidine (final concentration of 0.5 M) in Tris-HCl buffer pH 8 were added to the diluted CSF,
and samples were rotated overnight at 4°C. The beads were rinsed once
with 0.5 M guanidine and twice with 25 mM ammonium bicarbonate,
with centrifugation in between rinses. They were aspirated dry after the
final rinse and A␤ was eluted from the antibody– bead complex using 50
l of neat formic acid. After centrifuging the beads again, the formic acid
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calculations were performed with GraphPad
5.0. The coefficient of variation for quantitation was ⱕ3.8% for triplicate injections of the
same sample.
Gas chromatography-mass spectrometry and
calculation of 13C6-leucine enrichment. Plasma
and CSF 13C6-leucine enrichment was quantified using capillary gas chromatography mass
spectrometry (GC-MS; Agilent 6890N gas
chromatograph and Agilent 5973N mass selective detector). Leucine was converted to the
heptafluorobutyric propyl ester derivative;
13
C6-leucine (m/z 349 and 355) enrichment
was quantified using GC-MS in negative chemical ionization mode (Yarasheski et al., 1992;
Bateman et al., 2007b). 13C6-Leucine enrichment
was calculated as the tracer:tracee ratio (Wolfe et
al., 2005). The GC-MS instrument response was
calibrated using gravimetric standards of known
isotope enrichment.
Calculations of fractional synthesis rate, fractional clearance rate, and newly generated A␤.
The fractional synthesis rate (FSR) and fractional clearance rate (FCR) were calculated in
the traditional manner (Wolfe et al., 2005).
Figure 1. Illustration of A␤ stable-isotope-labeling kinetics study in CMP rhesus monkeys. A, CSF is collected from the cisterna FSR equals the slope of the labeled A␤ (hours
13
magna of the rhesus monkey. B, 13C6-leucine is infused from 0 to 12 h, and CSF collected from ⫺1 to 48 h. C, 13C6-leucine (Leu) is 2– 8) divided by plasma C6-leucine enrich13
␤ synthesis) during
ment
(precursor
pool
for
A
present in the plasma for the duration of infusion. D, The C6-leucine-labeled A␤ in rhesus monkey CNS increases during labeling
leucine infusion (hours 2– 8). FCR equals the
(production phase) and decreases thereafter (clearance phase).
slope of the natural logarithm of labeled A␤
during the clearance phase (hours 18 –33).
Newly generated A␤ was calculated as previsupernatant was transferred to a new tube and evaporated in a rotary
ously described as the product of the percentage of labeled A␤ (LC-MS
evaporator at 37°C for 30 min. The dried extract was reconstituted in 20
results) and the total A␤ concentration (ELISA results) (Bateman et al.,
l of 9:1 ammonium bicarbonate (25 mM): acetonitrile. The extract was
2009). All statistical calculations were performed with GraphPad 5.0.
digested with 400 ng of sequence grade trypsin (Promega) prepared in 25
mM ammonium bicarbonate and incubated at 37°C for 18 h.
6E10 immunoprecipitation. Protease inhibitors and guanidine were
Results
added to CSF (900 l) as described above. In addition, samples were
Translation of human CNS-SILK method for use in
spiked with 100 fmol (10 fmol/l) of isotope-labeled A␤ peptide
rhesus monkeys
A␤1-15[Ala(U- 13C3, 15N), Arg(U- 13C6, U- 15N4),Gly(U- 13C2, 15N)]
We adapted the human in vivo SILK method for use with CMP
(prepared in HPLC grade water) (Anaspec) before addition of 30 l of
rhesus monkeys. A summary of the protocol is shown in Figure 1.
6E10 bead slurry, after which they were rotated overnight at 4°C. The
13
C6-Leucine is intravenously administered to CMP rhesus monbeads were rinsed as described above and peptides and proteins were
keys
for 12 h; CSF is collected from the cisterna magna port
eluted from the antibody– bead complex using 50 l of neat formic
during and after administration (Fig. 1A,B). Labeled leucine enrichacid. After centrifugation, the formic acid supernatant was transment in plasma and CSF is measured by GC-MS (Yarasheski et al.,
ferred to autosampler vials and evaporated in a rotary evaporator at
1992) (Fig. 1C). The incorporation of the label into A␤ is quantitated
37°C for 30 min. The dried extract was reconstituted in 20 l of 5%
acetonitrile in 0.1% formic acid.
by immunoprecipitation paired with LC-MS (Bateman et al., 2006,
Liquid chromatography-mass spectrometry. A␤ extracts were analyzed
2007b) (Fig. 1D), and the results are used to calculate production
on a Thermo-Finnigan LTQ equipped with a New Objective nanoflow
and clearance rates.
ESI source. Peptides were separated by RP HPLC using an Eksigent
To translate the in vivo method from humans to monkeys, and
2D-LC nanoflow pump operating in 1D mode at a flow of 200 nl/min.
to achieve similar 13C6-A␤ labeling, two 13C6-leucine infusion
Five microliters of extract was injected onto a New Objective picofrit
protocols were evaluated. CMP rhesus monkeys were infused
column packed to 10 cm with 5 m Magic C18aq packing material
with 13C6-leucine (8 mg/kg/h) for either 21 or 12 h, and CSF was
(Michrom). Mobile phase A consisted of 0.1% formic acid in water, and
collected
approximately every 3 h for up to 48 h (Fig. 2). The
mobile phase B consisted of 0.1% formic acid in acetonitrile. The doubly
administration of 8 mg/kg/h 13C6-leucine resulted in fourfold
charged species of A␤ 17-28 were separated as previously described
higher plasma 13C6-leucine labeling than the ratios observed in
(Bateman et al., 2007b). The quadruply charged species of A␤1-14, 1-15,
1-16, and 1-17 were separated by applying a linear gradient from 2 to
humans (Bateman et al., 2006). Reduction of the infusion to 4
18% B over 30 min, followed by a rise to 90% B over 5 min, and returned
mg/kg/h 13C6-leucine for 12 h resulted in maximum plasma
13
to 2% B by 40 min.
C6-leucine labeling of 15%, which is more similar to human
Calculation of labeled protein ratio and quantitation of A␤1-14, 1-15,
studies, and thus was used for subsequent studies. The steady1-16, and 1-17. Percentage of labeled A␤ was calculated as the ratio of all
state labeling of A␤ exceeded the theoretical maximum when CSF
b- and y-tandem MS ion intensities from 13C6-A␤ 17–28 (m/z 666.5)
13
C6-leucine levels were used as the precursor pool (Fig. 2 A, 21 h
divided by all b- and y-tandem MS ion intensities from A␤ 17–28 (m/z
infusion).
In contrast, the steady-state labeling of A␤ approached
663.5) as previously described (Bateman et al., 2007b). The peak areas for
and did not exceed the maximum when using plasma 13C6A␤1-14, 1-15, 1-16, and 1-17 (MS 2 total ion currents) were calculated
leucine levels (Fig. 2 B, 21 h infusion). For this reason, subsequent
and normalized to the A␤1-15 isotope-labeled standard using Xcalibur’s
studies used plasma 13C6-leucine levels for labeled A␤ normalizaquantitation software. Results were exported to MS Excel. All statistical

6746 • J. Neurosci., May 12, 2010 • 30(19):6743– 6750

Cook et al. • GSI Demonstrates Alternative APP Metabolic Pathway

tion. By reducing the 13C6-leucine infusion
from 21 to 12 h, more sample time points
could be added to the A␤ clearance phase
which enabled more accurate clearance rate
calculations.
Intrasubject and intersubject variability for measurements of A␤ metabolism
were analyzed and compared with steadystate levels as measured by ELISA. The
same three animals were evaluated in two
separate studies, and calculated FCRs
were correlated between studies (r ⫽ Figure 2. The duration of 13C -labeling does not affect A␤ production estimates, and plasma better reflects the 13C -leucine
6
6
0.9969; supplemental Fig. 1 A, available at precursor for A␤ compared with CSF. A, B, Rhesus monkeys (n ⫽ 3) were infused with 13C6-leucine (8 mg/kg/h) for either 21 h
www.jneurosci.org as supplemental ma- (black, solid circle) or 12 h (red, solid triangle). The ratio of 13C-A␤ to 12C-A␤ from CSF was measured by LC-MS, and normalized
terial). Different individual monkeys (n ⫽ to the 13C6-leucine precursor enrichment measured in either CSF (A) or plasma (B). Values ⬎1 indicate incorrect estimates. Error
3) also showed similar FCRs with SEM bars represent SEM.
between 0.3 and 0.5%/h demonstrating
some biological variability between monkeys (supplemental Fig. 1 B, available at
www.jneurosci.org as supplemental material). FSR and FCR results were compared with levels of A␤. There was a
positive correlation between FSR and FCR
values and levels of A␤ (n ⫽ 9, FSR vs A␤
40 Pearson r ⫽ 0.76, p ⫽ 0.016; FSR vs
A␤42 Pearson r ⫽ 0.77, p ⫽ 0.015; FCR
vs A␤ 40 Pearson r ⫽ 0.41, p ⫽ 0.27; FCR
vs A␤ 42 Pearson r ⫽ 0.79, p ⫽ 0.03).
The 12 h optimized 13C6-leucine (4
mg/kg/h) infusion (n ⫽ 12 monkeys) Figure 3. Rhesus monkey CNS A␤ metabolism is similar to results observed in humans (Bateman et al., 2006). A, Optimized
demonstrated low intersubject variability 13C6-leucine labeling protocol was 4 mg/kg/h for 12 h, and CSF collected for 39 h (n ⫽ 12). B, Rates of A␤ production and clearance
for A␤ labeling kinetics at each time point are balanced in the rhesus monkey CNS. Combining results from three studies using identical protocols, the production and
sampled over 39 h (average SEM ⫽ 0.02, clearance rates were found to be consistent across n ⫽ 12 rhesus monkeys. There was no significant difference between the means
n ⫽ 12) (Fig. 3A). There were no signifi- observed for FSR and FCR, as measured by a Student’s t test. Error bars indicate SEM.
cant differences observed between gennewly generated CNS A␤ (Fig. 6 A). Similar results were observed
ders or across ages of the animals included in this study. The
in an extended study (240 h) with the 240 mg/kg GSI treatment
mean FSR (h 2– 8) was 10.7 ⫾ 0.6%/h (SEM) and the mean FCR
(Fig. 6 B) (unpaired t test, p ⫽ 0.0009). Area under the curve
(h 18 –33) was 9.9 ⫾ 0.5%/h (Fig. 3B); these values were not
(AUC) analysis for newly generated A␤ indicated a significant
significantly different ( p ⫽ 0.25).
difference between the means of the vehicle and GSI treatment
groups (ANOVA, p ⬍ 0.0001). The mean AUC not only reflected
CNS-penetrant ␥-secretase inhibitor decreases the generation
a dose-dependent decrease during the 13C6-leucine infusion
of newly produced A␤ in the brain of rhesus monkeys
(0 –12 h) (Fig. 6C), but also during the entire study (0 – 48 h) (Fig.
In a three-way crossover study, healthy male CMP rhesus mon6 D) (Tukey post hoc analysis, p ⬍ 0.001). During the 48 h samkeys (n ⫽ 6) were treated with single oral administration of two
pling period, the mean AUC of newly generated A␤ was reduced
doses of the CNS-penetrant GSI, MK-0752, and vehicle to evaluby 49% in the 60 mg/kg dose group and by 90% in the 240 mg/kg
ate effects on A␤ metabolism. MK-0752 concentrations were
GSI dose group ( p ⬍ 0.01) (Fig. 6 D).
quantified in plasma (Fig. 4 A) and CSF (Fig. 5A), showing peak
concentration at 2 h with both doses. The majority of the drug
was cleared from plasma and CSF by 36 h. Effects of this GSI on
CNS-penetrant ␥-secretase inhibitor alters levels of
noncanonical APP fragments
A␤ concentrations in the plasma and CSF were quantified using
ELISA and demonstrate a dose-related reduction of A␤ levels in
To evaluate alternative pathways of APP degradation in the presplasma (A␤40) ( p ⫽ 0.0012) and CSF (A␤40 and A␤42) ( p ⬍
ence of ␥-secretase inhibition, noncanonical forms of A␤ (e.g.,
0.001) as determined by a repeated-measures ANOVA (Figs. 4 B,
A␤ not produced by ␤- and ␥-secretase cleavage) were measured
in the CSF of rhesus monkeys (n ⫽ 6, 3/group) treated with a high
5 B, C). Plasma A␤ levels rebounded above baseline after GSI inhibition (60 mg/kg) ( p ⬍ 0.001 paired t test vehicle vs 60 mg/kg
dose of MK-0752 (240 mg/kg) versus vehicle. Four isoforms of
h 33– 48) (Fig. 4 B); in contrast, CSF A␤ levels did not overshoot
A␤ (A␤ 1-14, A␤ 1-15, A␤ 1-16, and A␤ 1-17) were quantified
baseline levels (Figs. 5 B, C). In an extended study designed to
from the CSF using internal standard controls. In animals treated
evaluate the rebound response of the higher dose of 240 mg/kg,
with the GSI, levels of A␤ 1-14, A␤ 1-15, and A␤ 1-16 increased
over vehicle levels, while levels of A␤ 1-17 decreased (unpaired t
an overshoot above baseline was observed in plasma 48 h after
test, p ⬍ 0.0001, Fig. 7). The expected reductions in plasma A␤40
treatment ( p ⬍ 0.001 unpaired t test vehicle vs 240 mg/kg h
and CSF A␤40 and A␤42 were demonstrated during the same
48 –240) (Fig. 4 D).
time (Figs. 4 D, 5 E, F ), while plasma A␤40 rebounded after 48 h
The GSI dose-dependently reduced newly synthesized CNS
(Fig. 4 D).
A␤ over 48 h, without any evidence of a rebound or overshoot of
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generation of CNS A␤ was significantly
reduced in response to ␥-secretase inhibition. However, in contrast to the periphery, production of CNS A␤ did not
rebound above baseline after cessation of
inhibition. Defining the metabolic fate of
APP in the CNS is critically important for
the development of ␥-secretase inhibitors
to treat AD, as a substrate build-up of APP
fragments could potentially lead to an
overshoot in neurotoxic amyloid peptides. The lack of A␤ rebound in the CNS
could be attributed to the shunting of APP
(possibly ␤ C-terminal fragments, e.g.,
C99) to ␥-secretase independent degradation. In support of this alternative, noncanonical processing, increased levels of
APP fragments A␤ 1-14, 1-15, and 1-16
were observed in CSF samples of animals treated with the GSI, while A␤ 1-17
was decreased. The CNS elimination of
APP through nonamyloidogenic pathFigure 4. Plasma levels of A␤ during and after ␥-secretase inhibition indicate peripheral A␤ rebound in rhesus monkeys ways strengthens the case for the use of
treated with a CNS-penetrant GSI. A, Concentration of GSI in rhesus monkey plasma after dosing with GSI. B, A␤ levels in rhesus ␥-secretase as a therapeutic target for
monkeys (n ⫽ 6), measured by ELISA are shown normalized to baseline. A dose–response effect on A␤ levels was observed with AD and may also be relevant for physi60 mg/kg and 240 mg/kg. Plasma A␤ levels in the 60 mg/kg dose group recovered to baseline after 24 h, and then increased above ological processing of APP.
baseline. Means between vehicle and 60 mg/kg from hours 33– 48 are significantly different (paired t test, ***p ⬍ 0.0001). C, D,
Many treatments have demonstrated
In an extended study (n ⫽ 6, 3/group), animals were treated with either vehicle or 240 mg/kg GSI. C, Concentration of GSI in rhesus efficacy in preclinical AD murine models;
monkey plasma after dosing with 240 mg/kg GSI. D, Plasma A␤ levels overshoot baseline after 48 h in 240 mg/kg GSI-treated however, to date, none have been successanimals (unpaired t test, ***p ⬍ 0.0001, h48 –240). (vehicle, black circle; 60 mg/kg, blue square; 240 mg/kg, red triangle). Error ful in clinical trials (Duff and Suleman,
bars indicate SEM.
2004). Failed translation from preclinical
models to clinical studies may be a result
of several reasons, including targeting of
the wrong molecular mechanism of disease, failure to sufficiently modulate the
target, or administration of the therapy too
late in the course of the disease (Bateman
and Klunk, 2008). For Alzheimer’s disease, one limiting factor for translation
from preclinical models to clinical trials is
the lack of animal models that closely reflect human A␤ CNS physiology; such
models would provide relevant information regarding the target, mechanism of
action, and therapeutic effectiveness.
Thus, there is a need to develop better
models of therapeutic targets that would
provide a bridge for the translation of murine models of amyloidosis to human triFigure 5. No evidence of central A␤ rebound in rhesus monkeys treated with a CNS-penetrant GSI. A, Concentration of GSI in
als in AD.
rhesus monkey CSF after dosing. B, C, A␤ levels in rhesus monkeys (n ⫽ 6), measured by ELISA, were normalized to baseline. A
The CMP rhesus monkey is a nonhudose–response effect on A␤ levels was observed with GSI treatment. A rebound effect was not observed in levels of CSF A␤40 (B)
man
primate model that enables repeat
or A␤42 (C). After 48 h, the A␤ levels with 240 mg/kg treatment only recovered to 50% of baseline, while the 60 mg/kg treatment
group reached baseline at 30 h without overshoot. D–F, In an extended study (n ⫽ 6, 3/group) A␤ levels returned to baseline sampling of CSF (Gilberto et al., 2003;
within 72 h of treatment (240 mg/kg), without rebound. (vehicle, black circle; 60 mg/kg, blue square; 240 mg/kg, red triangle). Nantermet et al., 2009; Sankaranarayanan
Error bars indicate SEM.
et al., 2009). Pairing this model with in
vivo SILK enables direct measurement of
newly generated CNS proteins and peptides
Discussion
such as A␤. Results demonstrate that A␤ metabolism in the rhesus
The results of this study demonstrate that A␤ metabolism in the
monkey is very similar to humans (Bateman et al., 2006), which
rhesus monkey is similar to healthy humans (Bateman et al.,
indicate that the CMP rhesus monkey model can be used for preclin2006), which is expected because there are no significant amyloid
ical drug discovery and development studies. Repeated measures
plaques present in the rhesus monkey brain at this age (Struble et al.,
(pre- and posttreatment) studies with a crossover design are espe1985). In conjunction with in vivo stable-isotope-labeling, new
cially powerful when coupled with the low intrasubject variability.
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This combination allows for the use of fewer
monkeys to clearly answer research questions (Fig. 3; supplemental Fig. 1, available
at www.jneurosci.org as supplemental
material).
There are similarities and differences between the metabolism of A␤ in rhesus monkeys and humans. As expected, the average
FSR and FCR are balanced in both the rhesus monkey (n ⫽ 12) (Fig. 3B) and human
(Bateman et al., 2006). However, rhesus
monkey CNS FSR and FCR are slightly
faster than human CNS FSR and FCR
(⬃10% per hour vs ⬃8% per hour, respectively; Fig. 3B) (Bateman et al., 2006). Other
than species differences, the observed disparity in A␤ metabolism may be due to CSF
sampling location. Human CSF was sampled by lumbar intrathecal catheter, whereas
monkey CSF was sampled at the cisterna
magna at the base of the head (Fig. 1A). The
more proximal sampling location could also
explain the slightly shorter delay in 13C6 incorporation observed in the monkeys versus
that seen in humans (4 h vs 5 h, respectively), which indicates that lumbar sampling only slightly delays the appearance of
newly generated A␤. Prior human studies
demonstrated individual changes in CSF A␤
levels by 100 – 400% over several hours
(Bateman et al., 2007a). In this study of nonhuman primate CSF, there were individual
CSF A␤ changes of 30 –50%. The group
changes in A␤ levels were similar between
human lumbar CSF samples and nonhuman primate CMP samples when averaged
(25–50% over a 24 h period). However,
CMP monkey samples did not demonstrate
a progressive rise in A␤ levels. Possible reasons for differences in the intrasubject
CSF A␤ variability and lack of CSF A␤
rise include species differences, behavioral
activity, site of sampling, frequency or
amount of sampling, and sleep/wake cycle
differences.
Findings in the nonhuman primate
model also have implications for human
studies. For example, in this study, we determined that plasma is more accurate
than CSF for leucine precursor measurements of CNS A␤ generation (Fig. 2). As
the CSF normalized ratio exceeded the
theoretical maximum of one, the CSF
13
C6-leucine is an underestimate of the
precursor pool labeling. The labeled
leucine precursor enrichment in monkey
plasma is higher than CSF, similar to results observed in humans (Bateman et al.,
2006). This suggests that plasma-labeled
leucine measurements are more accurate
for calculations of A␤ metabolism in human, as well as the nonhuman primate.
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Figure 6. Newly generated A␤ was reduced in response to GSI treatment in the CNS of rhesus monkeys (n ⫽ 6). A, C, D,
In a crossover study, male rhesus monkeys (n ⫽ 6) were infused with 13C6-leucine (4 mg/kg/h) for 12 h, and treated with
vehicle (black circle), 60 mg/kg GSI (blue square), or 240 mg/kg GSI (red triangle). B, In an extended study (n ⫽ 6, 3/group),
animals were treated with vehicle or 240 mg/kg GSI. A, B, Generation of new A␤ was partially blocked with administration
of 60 mg/kg, and nearly completely blocked at the 240 mg/kg dose as indicated by the dose-dependent decrease in the
amount of 13C6-leucine-labeled A␤ (LC-MS). C, D, AUC analysis of newly generated A␤ indicates that the means of newly
synthesized A␤ are significantly reduced by GSI treatment during the leucine infusion (0 –12 h) (C) and levels do not
recover within 48 h (D), as assessed by a repeated measures 1-way ANOVA ( p ⬍ 0.0001) and post hoc analysis (Tukey)
(*p ⫽ 0.01 to 0.05;**p ⫽ 0.001 to 0.01; ***p ⬍ 0.001). Error bars indicate SEM.

Figure 7. ␥-Secretase inhibition modulates levels of A␤ 1-14, 1-15, 1-16, and 1-17. Rhesus monkeys (n ⫽ 6, n ⫽ 3/group)
were treated with either vehicle (black, circle) or 240 mg/kg GSI (red, triangle). An increase in levels of A␤ 1-14 (A), A␤ 1-15 (B),
and A␤ 1-16 (C) was observed in GSI versus vehicle-treated animals during ␥-secretase inhibition. However, levels of A␤ 1-17 (D)
in treated animals were decreased versus vehicle. The means of the vehicle versus treated animals over 48 h were significantly
different for A␤ 1-14 (A), A␤ 1-15 (B), A␤ 1-16 (C), and A␤ 1-17 (D) (unpaired t test p ⬍ 0.0001).
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The utility of this CMP rhesus monkey translational model
was demonstrated by quantifying A␤ metabolism before and after acute exposure to the GSI MK-0752. A prior human GSI SILK
study indicates that a decrease in A␤ production can be measured
to a sensitive degree (Bateman et al., 2009). In this nonhuman
primate study, GSI efficacy (blocking A␤ production) and duration was higher compared with that observed in the human GSI
study. Possible reasons for these observed differences include the
GSI compound used, the dose of GSI administered, and, possibly,
species differences. The extended effect may be due to the longer
half-life of MK-0752 (10 h) in rhesus monkey versus LY450139
(2.5 h) in human (Siemers et al., 2005).
Consistent with previous observations (Lanz et al., 2004, 2006;
Michener et al., 2006; Rosen et al., 2006; Siemers et al., 2006;
Burton et al., 2008) plasma A␤ levels did rebound after the GSI
was cleared (Fig. 4). However, concentrations of A␤ in the CSF
did not overshoot baseline or placebo A␤ levels (Fig. 5). Measurement of production rates directly confirms that this GSI reduced
A␤ levels by decreasing the generation of new A␤ without a subsequent rebound (Fig. 6). These results suggest that the A␤ precursor is being degraded by another pathway during inhibition
(Portelius et al., 2009). In vitro studies have suggested that in the
presence of ␥-secretase inhibition, ␤-secretase and ␣-secretase
generate A␤ 1-14, 1-15, and 1-16, and that A␤ isoforms longer
than 1-16 are reduced (Portelius et al., 2009). Our results support
this hypothesis by demonstrating for the first time in a nonhuman primate model, the rise in A␤ 1-14, 1-15, and 1-16 with a
concurrent decrease of A␤ 1-17 (Fig. 7). Further, the time course
of altered APP metabolites indicates that A␤ 1-17 is possibly a
cleavage product of A␤ 1-40 and A␤ 1-42, as all are decreased at
similar times (0 – 48 h), while A␤ 1-14, 1-15, and 1-16 are increased during and after inhibition (0 –144 h). Potential candidates known to cleave at the A␤ 1-17 site include endothelin
converting enzyme, insulin-degrading enzyme, and matrix metalloproteinase-9 (Yan et al., 2006). These findings advance our understanding of the mechanisms of APP processing in the CNS, and
provide novel information about the effects of GSI therapy on APP
processing.
In conclusion, our study demonstrates that the effect of therapeutics developed to target A␤ production or clearance can be
evaluated directly in a preclinical, nonhuman primate model.
This will aid in the selection of clinical candidate compounds,
and optimization of dose and timing of drug administration in a
model which is similar to human A␤ physiology. In addition,
molecular mechanisms of CNS protein processing can be explored by using therapeutics, which modulate key CNS enzymes
with physiologically relevant models. These methods and findings hold promise to improve the likelihood of successful clinical
trials for the treatment of Alzheimer’s disease and other CNS
disorders.
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